ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients.
Karakike E, Dalekos GN, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papathanakos G, Kotsaki A, Chalvatzis S, Dimakopoulou V, Vechlidis N, Paramythiotou E, Avgoustou C, Ioakeimidou A, Kouriannidi E, Komnos A, Neou E, Rovina N, Stefanatou E, Milionis H, Nikolaidis G, Koutsoukou A, Damoraki G, Dimopoulos G, Zoumpos V, Eugen-Olsen J, Akinosoglou K, Gatselis NK, Koulouras V, Gkeka E, Markou N, Netea MG, Giamarellos-Bourboulis EJ.
Karakike E, et al. Among authors: ioakeimidou a.
J Innate Immun. 2022;14(3):218-228. doi: 10.1159/000519090. Epub 2021 Dec 1.
J Innate Immun. 2022.
PMID: 34852352
Free PMC article.